AbbVie Failed To Study Risks Of AndroGel, Jury Told

By Diana Novak Jones (September 18, 2017, 8:50 PM EDT) -- AbbVie dodged its responsibility to test AndroGel to see whether users faced an increased risk of heart attack, attorneys for a man suing the company told an Illinois federal jury Monday at the start of the second bellwether trial in the multidistrict litigation over testosterone gel products....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!